EML4-ALK融合基因在非小细胞肺癌中的临床意义

Lung cancer continues to be the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Molecular targeted therapy is the most promising development part in the treatment of NSCLC. In recent years, more and more attention has been focus...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2013
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000390/
https://www.ncbi.nlm.nih.gov/pubmed/23425902
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.02.07
_version_ 1783331708489170944
collection PubMed
description Lung cancer continues to be the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Molecular targeted therapy is the most promising development part in the treatment of NSCLC. In recent years, more and more attention has been focused on some new molecular targets in NSCLC, such as echinodem microtubule-associated protein-like4/anaplastic lymphoma kinase (EML4-ALK) fusion gene. This review will focus on the basic structure, clinicopathologic features, detection method, ALK inhibitor and therapeutic meaning of EML4-ALK in NSCLC.
format Online
Article
Text
id pubmed-6000390
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60003902018-07-06 EML4-ALK融合基因在非小细胞肺癌中的临床意义 Zhongguo Fei Ai Za Zhi 综述 Lung cancer continues to be the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Molecular targeted therapy is the most promising development part in the treatment of NSCLC. In recent years, more and more attention has been focused on some new molecular targets in NSCLC, such as echinodem microtubule-associated protein-like4/anaplastic lymphoma kinase (EML4-ALK) fusion gene. This review will focus on the basic structure, clinicopathologic features, detection method, ALK inhibitor and therapeutic meaning of EML4-ALK in NSCLC. 中国肺癌杂志编辑部 2013-02-20 /pmc/articles/PMC6000390/ /pubmed/23425902 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.02.07 Text en 版权所有©《中国肺癌杂志》编辑部2013 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
EML4-ALK融合基因在非小细胞肺癌中的临床意义
title EML4-ALK融合基因在非小细胞肺癌中的临床意义
title_full EML4-ALK融合基因在非小细胞肺癌中的临床意义
title_fullStr EML4-ALK融合基因在非小细胞肺癌中的临床意义
title_full_unstemmed EML4-ALK融合基因在非小细胞肺癌中的临床意义
title_short EML4-ALK融合基因在非小细胞肺癌中的临床意义
title_sort eml4-alk融合基因在非小细胞肺癌中的临床意义
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000390/
https://www.ncbi.nlm.nih.gov/pubmed/23425902
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.02.07

Ejemplares similares